We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanopatterned Microfluidic Chip Detects Cancer Markers

By LabMedica International staff writers
Posted on 13 Mar 2019
Image: The three-dimensional (3D) herringbone nanopatterned microfluidic chip that detects cancer faster (Photo courtesy of the University of Kansas).
Image: The three-dimensional (3D) herringbone nanopatterned microfluidic chip that detects cancer faster (Photo courtesy of the University of Kansas).
The performance of current microfluidic methods for exosome detection is constrained by boundary conditions, as well as fundamental limits to microscale mass transfer and interfacial exosome binding.

Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule amounts of blood. A device, which is called a "3D-nanopatterned microfluidic chip," could successfully detect cancer markers in the tiniest drop of blood or in a component of the blood called plasma.

Biochemists at the University of Kansas (Lawrence, KS, USA) and their colleagues have shown that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of tumor-associated exosomes in plasma (10 exosomes μL−1, or approximately 200 vesicles per 20 μL of spiked sample) that would otherwise be undetectable by standard microfluidic systems for biosensing. The nanopatterns promote microscale mass transfer, increase surface area and probe density to enhance the efficiency and speed of exosome binding, and permit drainage of the boundary fluid to reduce near-surface hydrodynamic resistance, thus promoting particle–surface interactions for exosome binding.

The scientists used the device for the detection, in 2 μL plasma samples from 20 ovarian cancer patients and 10 age-matched controls, of exosome subpopulations expressing CD24, epithelial cell adhesion molecule and folate receptor alpha proteins. They suggest exosomal folate receptor alpha as a potential biomarker for early detection and progression monitoring of ovarian cancer. The nanolithography-free nanopatterned device should facilitate the use of liquid biopsies for cancer diagnosis.

Yong Zeng, PhD, an associate professor of chemistry and the senior author of the study, said, “Historically, people thought exosomes were like 'trash bags' that cells could use to dump unwanted cellular contents. But, in the past decade scientists realized they were quite useful for sending messages to recipient cells and communicating molecular information important in many biological functions. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are really active compared to normal cells.” The study was published on February 25, 2019, in the journal Nature Biomedical Engineering.

Related Links:
University of Kansas

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)

Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Circulating Tumor DNA Test Identifies Complete Responders in Metastatic Cancer Immunotherapy

Immune checkpoint inhibitors have transformed treatment for many metastatic cancers, with some patients achieving durable disease control. However, clinicians remain uncertain about how long therapy should... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more